Jung Sun-Young, Sung Yoon-Kyoung, Kim Hyoungyoung, Cha Eom Ji, Jang Eun Jin, Yoo Dae-Hyun, Cho Soo-Kyung
College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, 04763, Republic of Korea.
Rheumatol Ther. 2022 Feb;9(1):139-149. doi: 10.1007/s40744-021-00392-y. Epub 2021 Nov 13.
To compare the effectiveness of azathioprine (AZA) and cyclosporine (CsA) as initial treatments for patients with idiopathic inflammatory myopathies (IIM).
A retrospective cohort study was conducted using information from the National Health Insurance Service database of Republic of Korea. Patients with IIM who had started AZA or CsA as initial treatment between January 2007 and December 2011 were selected for the study. They were followed from the day of treatment initiation to the occurrence of study outcomes or the end of the study until December 2016. Effectiveness outcomes, defined as switching the drug or adding immunosuppressants, and discontinuation of corticosteroids, were compared between the two groups. The Cox proportional-hazards model was used to calculate the adjusted relative risk (aRR) with 95% confidence interval (CI) between the AZA and CsA groups.
A total of 376 patients with incident IIM who used AZA (n = 288) or CsA (n = 88) were identified. The aRR of switching the drug or adding immunosuppressants (1.45 [95% CI 0.99-2.11]) was not significantly different between the CsA and AZA groups. Among patients who were treated with corticosteroids at baseline, the rate of discontinuation of corticosteroids was not different between the two groups (1.69 [95% CI 0.82-3.47]).
The effectiveness of AZA and CsA as initial treatments for the management of IIM was comparable.
比较硫唑嘌呤(AZA)和环孢素(CsA)作为特发性炎性肌病(IIM)患者初始治疗的有效性。
利用韩国国民健康保险服务数据库中的信息进行一项回顾性队列研究。选取2007年1月至2011年12月期间开始使用AZA或CsA作为初始治疗的IIM患者进行研究。从治疗开始之日起对他们进行随访,直至出现研究结果或研究结束(至2016年12月)。比较两组之间定义为换药或加用免疫抑制剂以及停用皮质类固醇的有效性结果。采用Cox比例风险模型计算AZA组和CsA组之间的调整相对风险(aRR)及95%置信区间(CI)。
共确定了376例使用AZA(n = 288)或CsA(n = 88)的新发IIM患者。CsA组和AZA组之间换药或加用免疫抑制剂的aRR(1.45 [95% CI 0.99 - 2.11])无显著差异。在基线接受皮质类固醇治疗的患者中,两组之间皮质类固醇的停用率无差异(1.69 [95% CI 0.82 - 3.47])。
AZA和CsA作为IIM初始治疗的有效性相当。